Evaluation of Tests for Lyme Disease

Spinhirne, Joel

doi:10.1128/jcm.44.4.1616-1617.2006

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the nature of the cause ( Borrelia Burgdorferi ) most available tests are for IgG/IgM. This strategy is characterized by high specificity (>98%) and reasonable but variable sensitivity (30–100%) depending on proper application, type of test, and disease stage [18,57,58,59]. However, as detection relies on the host immune response, it is ineffective until a few weeks after the infection [18,60].…”

Section: Components Of Paper-based Assaysmentioning

confidence: 99%

Designing Paper-Based Immunoassays for Biomedical Applications

Hristov

Rodriguez-Quijada

Gómez-Márquez

et al. 2019

Sensors

100

View full text Add to dashboard Cite

Paper-based sensors and assays have been highly attractive for numerous biological applications, including rapid diagnostics and assays for disease detection, food safety, and clinical care. In particular, the paper immunoassay has helped drive many applications in global health due to its low cost and simplicity of operation. This review is aimed at examining the fundamentals of the technology, as well as different implementations of paper-based assays and discuss novel strategies for improving their sensitivity, performance, or enabling new capabilities. These innovations can be categorized into using unique nanoparticle materials and structures for detection via different techniques, novel biological species for recognizing biomarkers, or innovative device design and/or architecture.

show abstract

Section: Components Of Paper-based Assaysmentioning

confidence: 99%

Designing Paper-Based Immunoassays for Biomedical Applications

Hristov

Rodriguez-Quijada

Gómez-Márquez

et al. 2019

Sensors

100

View full text Add to dashboard Cite

show abstract

A Concise Critical Analysis of Serologic Testing for the Diagnosis of Lyme Disease

DeBiasi

2014

Curr Infect Dis Rep

View full text Add to dashboard Cite

Diagnostic testing for Lyme disease in the clinical setting primarily relies on assessment of serologic responses to infection, with the exception of the early localized phase of disease, in which the diagnosis must be made clinically, due to the recognized insensitivity of serologic testing at this phase of disease. For the diagnosis of early disseminated and late disease, the Centers for Disease Control and Prevention (CDC) recommends a two-tiered approach to testing consisting of initial IgM and IgG quantitative enzyme-linked immunosorbent assay (ELISA), followed by confirmation of all indeterminate or positive ELISA tests with separate IgG and IgM Western blots. This critical analysis addresses the sensitivity, specificity, and predictive value of serologic testing for Lyme disease in early localized, early disseminated, and late disease. Other testing modalities currently under evaluation are also discussed, including IgG vlsE C6 peptide ELISA, other two-tiered testing strategies, rapid diagnostics, and PCR. An understanding of the strengths and limitations of currently available testing for Lyme disease is critical for appropriate diagnosis.

show abstract

Evaluation of Tests for Lyme Disease

Cited by 2 publications

References 9 publications

Designing Paper-Based Immunoassays for Biomedical Applications

Designing Paper-Based Immunoassays for Biomedical Applications

A Concise Critical Analysis of Serologic Testing for the Diagnosis of Lyme Disease

Contact Info

Product

Resources

About